Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

被引：2
|
作者：
Wei, Lai [1 ,2 ,3 ]
Mei, Dan [1 ,2 ,3 ]
Hu, Sijia [1 ,2 ,3 ]
Du, Shufang [1 ,2 ,3 ]
机构：
[1] Sichuan Univ, West China Hosp, State Key Lab Oral Dis, Stomatol Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China
来源：
FUTURE MEDICINAL CHEMISTRY | 2024年 / 16卷 / 15期
关键词：
AR; BMI1; DNMTs; drug design; EHMT2 (G9a); EZH2; inhibitors; structure-activity relationship; SMALL-MOLECULE INHIBITOR; GROUP PROTEIN EZH2; HOMOLOG; EZH2; ANDROGEN RECEPTOR; STEM-CELLS; SELECTIVE-INHIBITION; CANCER-CELLS; POLYCOMB; METHYLATION; COMPLEX;
D O I：
10.1080/17568919.2024.2380243
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a crucial role in tumor progression by regulating gene expression. EZH2 inhibitors have emerged as promising anti-tumor agents due to their potential in cancer treatment strategies. However, single-target inhibitors often face limitations such as drug resistance and side effects. Dual-target inhibitors, exemplified by EZH1/2 inhibitor HH-2853(28), offer enhanced efficacy and reduced adverse effects. This review highlights recent advancements in dual inhibitors targeting EZH2 and other proteins like BRD4, PARP1, and EHMT2, emphasizing rational design, structure-activity relationships, and safety profiles, suggesting their potential in clinical applications.
引用
收藏
页码：1561 / 1582
页数：22
相关论文
共 50 条
  • [11] EZH2: novel therapeutic target for human cancer
    Li, Long-Yuan
    BIOMEDICINE-TAIWAN, 2014, 4 (01): : 1 - 6
  • [12] EZH2 in Bladder Cancer, a Promising Therapeutic Target
    Martinez-Fernandez, Monica
    Rubio, Carolina
    Segovia, Cristina
    Lopez-Calderon, Fernando F.
    Duenas, Marta
    Paramio, Jesus M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (11): : 27107 - 27132
  • [13] Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
    Lanzi, Cinzia
    Arrighetti, Noemi
    Pasquali, Sandro
    Cassinelli, Giuliana
    BIOCHEMICAL PHARMACOLOGY, 2023, 215
  • [14] Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors
    Guo, Zhirong
    Sun, Yameng
    Liang, Liyun
    Lu, Wenhua
    Luo, Bingling
    Wu, Zhouming
    Huo, Bitao
    Hu, Yumin
    Huang, Peng
    Wu, Qiang
    Wen, Shijun
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (09) : 6573 - 6592
  • [15] Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
    Ma, Linlin
    Yan, Yuqian
    Bai, Yang
    Yang, Yinhui
    Pan, Yunqian
    Gang, Xiaokun
    Karnes, R. Jeffrey
    Zhang, Jun
    Lv, Qiubo
    Wu, Qiang
    Huang, Haojie
    THERANOSTICS, 2019, 9 (17): : 5020 - 5034
  • [16] Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy
    Chen, Xinye
    Wang, Cheng
    Lu, Dehua
    Luo, Heng
    Li, Shang
    Yin, Fucheng
    Luo, Zhongwen
    Cui, Ningjie
    Kong, Lingyi
    Wang, Xiaobing
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 91
  • [17] Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
    Shinohara, Haruka
    Sawado, Rie
    Nakagawa, Makoto
    Hattori, Ayuna
    Yamagata, Kazutsune
    Tauchi, Kimiharu
    Ito, Jumpei
    Kuwahara, Yasumichi
    Okuda, Tsukasa
    Ogawa, Chitose
    Kitabayashi, Issay
    MOLECULAR THERAPY ONCOLYTICS, 2022, 27 : 14 - 25
  • [18] Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
    Italiano, Antoine
    PHARMACOLOGY & THERAPEUTICS, 2016, 165 : 26 - 31
  • [19] Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
    Keller, Patricia J.
    Adams, Elizabeth J.
    Wu, Rentian
    Cote, Alexandre
    Arora, Shilpi
    Cantone, Nico
    Meyer, Rosana
    Mertz, Jennifer A.
    Gehling, Victor
    Cui, Jike
    Stuckey, Jacob I.
    Khanna, Avinash
    Zhao, Feng
    Chen, Zehua
    Yu, Ziyang
    Cummings, Richard T.
    Taimi, Mohammed
    Lakhani, Nehal J.
    Rasco, Drew
    Gutierrez, Martin
    Duska, Linda
    Devitt, Michael
    Rippley, Ronda
    Levell, Julian
    Truong, Jennifer
    Wang, Jing
    Sun, Kaiming
    Trojer, Patrick
    CANCER RESEARCH, 2024, 84 (15) : 2501 - 2517
  • [20] Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells
    Xiong, Xifeng
    Zhang, Jinli
    Liang, Weiguo
    Cao, Wenjuan
    Qin, Shengnan
    Dai, Libing
    Ye, Dongping
    Liu, Zhihe
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (02) : 623 - 628
12345